News

Aerie Pharmaceuticals (Aerie) has reported positive results from a phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three

EMD Chemicals (EMD), a subsidiary of Germany-based Merck, has entered into a research and commercial collaboration with MitoSciences. The new collaboration allows for co-development of multiplex immunoassay products

Sosei Group (Sosei) has provided updates on NVA237 and QVA149 trials. The company is planning to proceed the phase III trials with NVA237, which commenced in June 2009.

Aethlon will contribute into ESI all exosome-related patents and patents pending. Jim Joyce, chairman and chief executive officer of Aethlon said, “The ability to reduce circulating exosomes would

Halozyme Therapeutics (Halozyme) and Roche have reported dosing of the first patient in a phase 3 registration trial using Enhanze technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous

ZyGEM and Phthisis Diagnostics have entered into an agreement to develop products enabling the detection of infectious pathogens in complex samples, such as stool, blood and water. Reportedly,

Their project is one of 76 grants announced by the Gates Foundation in the third funding round of Grand Challenges Explorations. To receive funding Wright and Haselton showed

The Gen-Probe’s complaint also alleges that BD’s ProbeTec Female Endocervical and Male Urethral Specimen Collection Kits for Amplified Chlamydia trachomatis/Neisseria gonorrhoeae (CT/GC) DNA Assays used with the Viper

Optigenex has entered into a supply and license Agreement with Suracell to provide its patented ingredient AC-11 for use in a focused nutritional and age management dietary supplement